eIF3a基因多态性与卵巢癌铂类药物治疗敏感性的关系  

eIF3a gene polymorphism and chemo-sensitivity to platinum-based drugs in ovarian cancer

作　　者：章采奕 张淑芬 刘英姿[2] 田焱[1] 李新国[1] 张瑜[1] 

机构地区：[1]中南大学湘雅医院妇产科,长沙410008 [2]中南大学湘雅医院临床药理研究所,长沙410008

出　　处：《中南大学学报（医学版）》2015年第6期617-622,共6页Journal of Central South University ：Medical Science

基　　金：湖南省科学技术厅科技计划基金(2013FJ4114);2012年度湖南省青年骨干教师培养对象项目~~

摘　　要：目的:研究真核起始因子3a(eukaryotic initiation factor 3a,e IF3a)基因rs3824830,rs77382849,rs10787899,rs3740556位点多态性与卵巢癌铂类药物治疗敏感性的关系。方法:选取57例初次术后完成以铂类为基础的联合化疗6周期的卵巢癌患者,用基质辅助激光解吸电离飞行时间质谱(matrix assisted laser desorption ionization time-of-fl ight mass spectrometry,MALDI-TOF MS)技术检测其外周血中e IF3a多态性位点基因型,分析每个位点不同基因型与卵巢癌铂类药物治疗敏感性的关系。结果:e IF3a rs3824830检测出3个基因型,即AA,GA,GG,基因型分布频率分别为43.86%,36.84%和15.79%(2例未测出,3.51%);e IF3a rs77382849检测出2个基因型,即CC和TC,基因型分布频率分别为85.96%和12.28%(1例未测出,1.76%);e IF3a rs10787899检测出3个基因型,即GG,GA,AA,基因型分布频率分别为26.32%,47.36%和26.32%。卵巢癌铂类耐药组和敏感组的平均年龄和FIGO分期间差异有统计学意义(P<0.05)。e IF3a rs10787899GA基因型比GG基因型携带者更容易对铂类化疗药物产生耐药性,比值比上升2.676倍(95%CI:0.544~13.159),e IF3a rs10787899 AA基因型携带者比GG基因型携带者更容易对铂类化疗药物产生耐药性,比值比上升5.419倍(95%CI:0.964~30.471),但平衡年龄和分期后,差异均没有统计学意义(P>0.05)。所有血液样本中,e IF3a rs3740556位点的基因型均为GG。结论:e IF3a rs3740556位点未检测出突变基因型,e IF3a rs3824830,rs77382849,rs10787899位点的基因多态性与卵巢癌铂类药物治疗的敏感性无相关性。Objective: To investigate the relationship between the eukaryotic initiation factor 3a(e IF3a)polymorphisms and chemo-sensitivity to platinum-based drug in ovarian cancer. Methods: Matrix-assisted laser desorption ionization time-of-flight mass spectrometry(MALDITOF MS) analysis was performed to detect 57 cases of e IF3 a polymorphic genotypes(rs3824830, rs77382849, rs10787899 and rs3740556) after platinum-based chemotherapy drugs up to 6 cycles in primary ovarian cancer. The association between these gene sites was analyzed. Results: There were 3 genotypes for e IF3 a rs3824830, named AA, GA and GG. The frequency distribution for them was 43.86%, 36.84% and 15.79%(2 cases did not detect the genotype, 3.51%), respectively. There were 2 genotypes for e IF3 a rs77382849, named CC and TC. The frequency distribution for them was 85.96% and 12.28%(1 case did not detect the genotype, 1.76%), respectively. There were 3 genotypes for e IF3 a rs10787899, named GG, GA and AA, respectively. The frequency distribution for them was 26.32%, 47.36% and 26.32%, respectively. There were significant difference in different genotypes between age group and FIGO stage(P<0.05). The genotype of e IF3 a rs10787899 GA was easier to resist platinum drug compared with the GG genotype and the odds ratio could be increased by 2.676(95%CI: 0.544–13.159). The genotype of e IF3 a rs10787899 AA was easier to resist platinum drug compared with the GG genotype and the odds ratio could be increased by 5.419(95%CI: 0.964–30.471). Rebalanced by age and FIGO stage, there was no significant difference(P>0.05) among these genotype groups. In all blood samples, there was only one genotype for e IF3 a rs3740556, named GG. Conclusion: There is no mutation genotype in e IF3 a rs3740556 loci. Polymorphism in the e IF3 a rs3824830, rs77382849 and rs10787899 doesn’t affect the response of ovarian cancer to platinumbased chemotherapy.

关 键 词：卵巢癌 真核细胞翻译起始因子3a 单核苷酸多态性 铂类药物 化疗敏感性 

分 类 号：R737.31[医药卫生—肿瘤]